March 29, 2006

Oncolytics Biotech Inc., the Calgary AB based company "focus[ing] on the discovery and development of pharmaceutical products for the treatment of a wide variety of human cancers," recently obtained a patent regarding the prevention of reovirus recognition. U.S. Patent No. 7,014,847 ("Methods for Preventing Reovirus Recognition for the Treatment of Cellular Proliferative Disorders"), issued on March 21st, discloses several methods "directed to the enhancement of the effectiveness of existing reovirus therapies in the treatment of proliferative disorders." The independent claim of the patent teaches a method of treating a mammalian neoplasm by performing a step from a group of administering immune suppressive agents to neoplastic cells, removing anti-reovirus antibodies, administering anti-antireovirus antibodies, and suppressing the immune system, and then "administering to the mammal an oncolytically effective amount of reovirus; wherein the neoplasm comprises cells in which the phosphorylation of PKR is prevented." Oncolytics currently has a number of clinical trials ongoing regarding its REOLYSIN® product, which, according to its website, "has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway," and that "REOLYSIN® may represent a novel treatment for Ras activated tumour cells and some cellular proliferative disorders." This is the 15th U.S. patent issued to Oncolytics.

U.S. Patent No. 7,014,847: LINK
Oncolytics Biotech Press Release: LINK
Oncolytics Biotech Website: LINK


Post a Comment

WIPO Press Releases

WIPO General News

Patent References

Click HERE to search issued U.S. Patents

Click HERE to search published U.S. Patent Applications

Click HERE to browse the MPEP (E8r6 in HTML and PDF, and E8r7 in PDF)

Click HERE to search patent assignments recorded with the USPTO

Click HERE to search Title 37 of the Code of Federal Regulations (rev. 7/1/08)

Click HERE to browse Title 35 of the U.S. Code

Click HERE to view current USPTO fees


Copyright 2006-2010, Mark Reichel. The Daily Dose of IP is my personal website, and I am not providing any legal advice or financial analysis. Any views expressed herein should not be viewed as being the views of my employer, Ice Miller LLP. Any comments submitted to this blog will not be held in confidence and will not be considered as establishing an attorney-client relationship. Information submitted to this blog should be considered as being public information, and the submitter takes full responsibility for any consequences of any information submitted. No claims, promises, or guarantees are made or available regarding the completeness or accuracy of the information contained in this blog or otherwise available by searching from or linking away from this blog.

EPO Updates

Trademark References

Click HERE to search issued and pending U.S. Trademarks

Click HERE to search TTAB proceedings (via TTABVUE)

Click HERE to search trademark assignments recorded with the USPTO

The DDIP Author

Mark Reichel
Reichel IP LLC

I am a patent attorney with Reichel IP LLC, where I concentrate my practice on patent drafting and prosecution, trademarks, and general intellectual property matters. I currently focus on the preparation and prosecution of medical device and other life sciences patent applications, and being actively involved in a number of local not-for-profit organizations.

Click HERE to view my full professional bio at Reichel IP LLC.


Click HERE to join the e-mail list for my blog

Click HERE to provide feedback on the DDIP blog

Fellow Blogs/Bloggers

AwakenIP (Kuester)
Counterfeit Chic (Scafidi)
I/P Updates (Heinze)
Internet Cases (Brown)
Likelihood of Confusion (Coleman)
Patent Baristas (Albainy-Jenei)
Patent Docs (Zuhn et al.)
Patently-O (Crouch)
The 271 Patent Blog (Zura)
The Ice Loop (Ice Miller LLP)
The Indiana Law Blog (Oddi)
The Invent Blog (Nipper)
The Patent Prospector (Odom)
The TTABlog (Welch)